• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features).在一项有亚阈值轻躁狂(混合特征)的重性抑郁障碍研究中进行的评定监测和可靠性研究。
Int J Methods Psychiatr Res. 2018 Dec;27(4):e1729. doi: 10.1002/mpr.1729. Epub 2018 Jun 26.
2
Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression.双盲、安慰剂对照研究利鲁唑单药治疗双相 I 型抑郁症。
Psychiatry Clin Neurosci. 2020 Dec;74(12):635-644. doi: 10.1111/pcn.13137. Epub 2020 Sep 24.
3
Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.鲁拉西酮治疗伴有混合(亚综合征性轻躁狂)特征的双相抑郁:一项随机安慰剂对照试验的事后分析
J Clin Psychiatry. 2015 Apr;76(4):398-405. doi: 10.4088/JCP.14m09410.
4
Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial.拉瑞沙酮对伴有亚阈值轻躁狂症状(混合特征)的重性抑郁障碍患者性功能的影响:一项安慰剂对照试验的结果。
J Clin Psychiatry. 2018 Aug 7;79(5):18m12132. doi: 10.4088/JCP.18m12132.
5
Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.伴有混合特征的重性抑郁障碍的治疗:一项随机、双盲、安慰剂对照研究。
Am J Psychiatry. 2016 Apr 1;173(4):400-7. doi: 10.1176/appi.ajp.2015.15060770. Epub 2015 Nov 10.
6
Audio-digital recordings for surveillance in clinical trials of major depressive disorder.用于重度抑郁症临床试验监测的音频数字记录。
Contemp Clin Trials Commun. 2019 Jan 8;14:100317. doi: 10.1016/j.conctc.2019.100317. eCollection 2019 Jun.
7
Audio-digital recordings used for independent confirmation of site-based MADRS interview scores.用于独立确认基于现场的 MADRS 访谈评分的音频数字记录。
Eur Neuropsychopharmacol. 2014 Nov;24(11):1760-6. doi: 10.1016/j.euroneuro.2014.08.016. Epub 2014 Sep 6.
8
Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis.鲁拉西酮治疗伴有混合特征和易激惹的重度抑郁症:一项事后分析。
CNS Spectr. 2017 Apr;22(2):228-235. doi: 10.1017/S1092852917000232. Epub 2017 Mar 16.
9
Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale.鲁拉西酮治疗混合性抑郁状态的疗效:标准评定量表与 Koukopoulos 混合性抑郁评定量表的比较。
J Clin Psychopharmacol. 2020 Sep/Oct;40(5):491-494. doi: 10.1097/JCP.0000000000001261.
10
Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.阿塞那平治疗伴有混合发作的双相 I 型障碍患者的躁狂和抑郁症状的效果:事后分析结果。
J Affect Disord. 2013 Feb 15;145(1):62-9. doi: 10.1016/j.jad.2012.07.013. Epub 2012 Aug 4.

引用本文的文献

1
Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward.应对中枢神经系统临床试验中安慰剂反应挑战的现有及新兴技术:前景、陷阱与未来之路
Innov Clin Neurosci. 2024 Mar 1;21(1-3):19-30. eCollection 2024 Jan-Mar.
2
Audio-digital recordings for surveillance in clinical trials of major depressive disorder.用于重度抑郁症临床试验监测的音频数字记录。
Contemp Clin Trials Commun. 2019 Jan 8;14:100317. doi: 10.1016/j.conctc.2019.100317. eCollection 2019 Jun.

本文引用的文献

1
Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-controlled study.伴有阈下轻躁狂(混合特征)的重度抑郁症:一项多区域、安慰剂对照研究中入组患者的临床特征
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jul 4;68:9-14. doi: 10.1016/j.pnpbp.2016.02.007. Epub 2016 Feb 22.
2
Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.伴有混合特征的重性抑郁障碍的治疗:一项随机、双盲、安慰剂对照研究。
Am J Psychiatry. 2016 Apr 1;173(4):400-7. doi: 10.1176/appi.ajp.2015.15060770. Epub 2015 Nov 10.
3
Impact of BPRS interview length on ratings reliability in a schizophrenia trial.在一项精神分裂症试验中,简明精神病评定量表(BPRS)访谈时长对评分可靠性的影响。
Eur Neuropsychopharmacol. 2015 Mar;25(3):312-8. doi: 10.1016/j.euroneuro.2014.11.023. Epub 2014 Dec 13.
4
Audio-digital recordings used for independent confirmation of site-based MADRS interview scores.用于独立确认基于现场的 MADRS 访谈评分的音频数字记录。
Eur Neuropsychopharmacol. 2014 Nov;24(11):1760-6. doi: 10.1016/j.euroneuro.2014.08.016. Epub 2014 Sep 6.
5
Mixed Specifier for Bipolar Mania and Depression: Highlights of DSM-5 Changes and Implications for Diagnosis and Treatment in Primary Care.双相躁狂和抑郁的混合说明符:《精神疾病诊断与统计手册》第5版的变化要点及其对初级保健中诊断和治疗的影响
Prim Care Companion CNS Disord. 2014;16(2). doi: 10.4088/PCC.13r01599. Epub 2014 Apr 17.
6
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.DSM-5 躁狂发作混合特征:使用阿塞那平临床试验数据评估抑郁特征对严重程度和治疗结果的影响。
J Affect Disord. 2013 Sep 5;150(2):378-83. doi: 10.1016/j.jad.2013.04.025. Epub 2013 May 25.
7
Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity.作为阈下双相性结果的《精神疾病诊断与统计手册》第四版重性抑郁障碍的异质性
Arch Gen Psychiatry. 2009 Dec;66(12):1341-52. doi: 10.1001/archgenpsychiatry.2009.158.
8
Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD.1380例双相情感障碍患者抑郁发作期间的躁狂症状:来自双相情感障碍系统治疗强化项目(STEP-BD)的研究结果
Am J Psychiatry. 2009 Feb;166(2):173-81. doi: 10.1176/appi.ajp.2008.08050746. Epub 2009 Jan 2.
9
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia.在一项针对精神分裂症的多中心临床试验中,通过实时双向视频使用远程集中评估者。
J Clin Psychopharmacol. 2008 Dec;28(6):691-3. doi: 10.1097/JCP.0b013e31818c9ba3.
10
Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA).蒙哥马利-艾斯伯格抑郁评定量表结构化访谈指南(SIGMA)的编制与信度
Br J Psychiatry. 2008 Jan;192(1):52-8. doi: 10.1192/bjp.bp.106.032532.

在一项有亚阈值轻躁狂(混合特征)的重性抑郁障碍研究中进行的评定监测和可靠性研究。

Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features).

机构信息

Bracket Global, LLC, Boston, Massachusetts, USA.

Sunovion Pharmaceuticals, Fort Lee, New Jersey, USA.

出版信息

Int J Methods Psychiatr Res. 2018 Dec;27(4):e1729. doi: 10.1002/mpr.1729. Epub 2018 Jun 26.

DOI:10.1002/mpr.1729
PMID:29943445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6877125/
Abstract

OBJECTIVES

Site-independent ratings surveillance assessed ratings reliability in a clinical trial.

METHODS

Inter-rater reliability was assessed at the screen visit in a 6-week, double-blind, placebo-controlled study of lurasidone for the treatment of major depressive disorder (MDD) with subthreshold hypomanic ("mixed") symptoms (clinicaltrials.gov NCT01421134). Site-based Montgomery-Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) interviews were paired with 184 site-independent ratings derived from audio-digital recordings.

RESULTS

The paired MADRS and YMRS scores were highly correlated (r = 0.708 and 0.885, respectively) and generated minimal scoring discordance. The surveillance program identified 14 MADRS scores (7.6% of this sample) that were below the study entry criterion (MADRS ≥26) and resulted in screen failure. When present, paired scoring discordance was associated with symptom severity, interview length, interview quality, and the level of patient cooperation. Higher severity scores (MADRS ≥40 and YMRS ≥15) were associated with greater paired scoring discordance. Further, MADRS scores <30 and short MADRS interviews conducted in ≤12 min revealed significantly more pairs of discordant outliers (p = 0.04 and 0.009, respectively).

CONCLUSIONS

The findings suggest that MDD patients with mixed features can be reliably assessed, that paired site-based and site-independent assessments were generally concordant, and that ratings surveillance may reinforce ratings precision.

摘要

目的

独立于地点的评分监测评估了临床试验中的评分可靠性。

方法

在一项为期 6 周、双盲、安慰剂对照的研究中,对伴有阈下轻躁狂(“混合”)症状的重度抑郁症(MDD)患者进行了 lurasidone 治疗,在筛选访视时评估了组间可靠性(clinicaltrials.gov NCT01421134)。基于地点的蒙哥马利-阿斯伯格抑郁评定量表(MADRS)和 Young 躁狂评定量表(YMRS)访谈与 184 个源自音频数字化录音的独立地点评分相配对。

结果

配对的 MADRS 和 YMRS 评分高度相关(r 值分别为 0.708 和 0.885),且评分差异极小。监测计划识别出 14 个 MADRS 评分(该样本的 7.6%)低于研究入组标准(MADRS≥26),导致筛选失败。当存在配对评分差异时,其与症状严重程度、访谈时长、访谈质量和患者合作程度相关。更高的严重程度评分(MADRS≥40 和 YMRS≥15)与更大的配对评分差异相关。此外,MADRS 评分<30 和 MADRS 访谈时间≤12min 的情况,显示出明显更多的配对异常值(p 值分别为 0.04 和 0.009)。

结论

这些发现表明,伴有混合特征的 MDD 患者可以进行可靠评估,基于地点和独立地点的配对评估通常是一致的,并且评分监测可能会增强评分的精准性。